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Haemoglobin occupies a special position among the many proteins of man and 
other animals. It is among the most abundant of proteins and one of the best 
studied. Traditionally, haemoglobin has occupied the leading edge in the 
development of our understanding on the structure, function and biosynthesis 
of proteins and more recently in molecular biology and medicine. 
Approximately fifteen years since a-thalassaemia was documented as the first 
molecular disease, we take this opportunity to review some of the most salient 
features of haemoglobin molecular biology and relate this body of knowledge to 
the development of strategies that contribute in understanding other problems in 
molecular medicine and improve patient care. Haemoglobin R & D programmes 
offer tremendous opportunities to enhance the education and training of young 
scientists in developing countries and help to develop high quality services. 
The term molecular disease is relatively new in medical nomenclature. It refers 
to the study of a range of conditions which are due to abnormalities in the 
sequence or organisation of the nuclear or mitochondrial nucleic acids. These 
encompass genetics, oncology and infectious disease, typically viral infections. 
At the level of pro tein structure, the haemoglobin molecule is a tetramer 
consisting of two pairs of dissimilar globin polypeptides. Each one of these is 
associated with a haeme prosthetic group; haeme being the ligand or oxygen 
binding site. As in the case of other animals, the bulk haemoglobin solution 
isolated from peripheral erythrocytes of man, is heterogenous. Its components 
which differ in subunit composition and developmental expression can be 
resolved by advanced biochemical techniques. Electrophoresis has been one of 
the most versatile techniques for haemoglobin analysis. !so-electric focusing is 
a modern modification which permits fine resolution of abnonnal haemoglobin 
and is suitable for clinical investigation and population testing. A typical 
separation of the adult Hb A from that of the foetal Hb Fas well as some of the 
more common abnormal haemoglobins such as Hb S (a.213i 6 Val), common 
among peoples of African descent and Hb F Malta I (or a.2y 2 117 Arg), a variant 
present in about 2% of newborn in Malta is shown in Fig. 1. 
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Another approach in haemoglobin analysis, employs one of the many possible 
chromatographic procedures, especially high performance liquid 
chromatography with ion exchange or reverse phase matrices. They are 
extensively used in fae investigation of normal and abnormal haemoglobins as 
well as in providing services for patients. Ion exchange chromatography has 
developed into one of the most effective steps in downstream processing of 
biotechnology products. It is interesting to note that many of these analytical 
and preparative techniques have been developed in different laboratories 
utilising haemoglobin as a model protein. 
The succession of different haemoglobins during the course of human 
development is characterised by at least two genetic switches and perhaps even 
higher levels of complexity. During the first six week of gestation the 
haemoglobin appearing in the yolk sac, is composed of Rb Gowers I or C2e2(1) 
and II or a.2e2(1) and Rb Portland or C2r 2(2,3) which are assembled from the 
embryonic e and C g~obin chains. These are then replaced by the permanent a. 
globin chains and the two types of y globin chains, Gy and Ay(4), that differ 
from each other at position 131 of the polypeptide chain which is glycine in Gy 
and alanine in Ay. The relative level of expression of the two y chains is 
genetically controlled. Around the time of birth, a second genetic switch shuts 
down the production of they chains and turns on the production of the p chains 
of Rb A (a.2Pi) and the minor o component of Rb A2 (a.20i) (Fig. 2). 
Each of these seven polypeptides is represented at least once in nuclear DNA by 
corresponding structural genes. The a. and the y globin genes are duplicated. 
The z and a. genes occur on chromosome #16 while the e, y, o and p genes are 
on chromosome #11. Both sets of genes occur on their respective chromosomes 
in the order in which they are developmentally expressed. 
The perinatal shutdown of Rb F, is incomplete. In fact, small quantities of Rb F 
persist in normal adults at levels below 1 % of the total haemoglobin. However, 
this is restricted to a subpopulation of erythrocytes designated F-cells. This is a 
typical example of tissue heterogeneity in gene expression and undoubtedly 
reflects complex gene control which is only now being unravelled(see 5 for 
references). It reflect~ similar levels of possible complexity and heterogeneity of 
gene expression in other tissues such as skin and gastro-intestinal tissue. 
Following transcription, the primary RNA transcript undergoes a series of 
processes wherein the intron sequencies are spliced and the resulting RNA 
matured through capping and the addition of adenyl residues at the 3'tail end. 
The final mRNA is exported into the cytppJ~sm fQr . translation into globin 
monomers and subsequent assembly into dimers and tetramers. Hereditary 
abnormalities can affect any one of these biochemical steps and can thus impair 
gene expression as they commonly do in thalassaemia. Many abnormalities of 
splicing and mRNA processing have been identified in globin(6) as well as 
other genes. 
At a higher level of resolution, the structural organisation of a typical globin 
gene can be understood in terms of regions of DNA that are critical for the 
control of gene activity. These include the locus control region (LCR), the 
promoter region with its RNA polymerase binding sites, the cap site, the 
initiation codon, the coding regions or exons, intervening sequencies or introns, 
with their invariant dinucleotides at the intron-exon junction, the termination and 
polyadenylation signals. 
DNA abnormalities can be considered to fall in two broad categories with some 
overlap. One class is due to base pair substitutions that alter the coding 
sequence in the exons and hence in the amino acid sequence of the protein 
product and result in the production of haemoglobin variants. Another class is 
due to deletion or base pair substitution that impairs gene expression and results 
in globin deficiencies typical of the thalassaemias(6). 
Approximately 600 abnormal haemoglobins each differing in the amino acid 
sequence of one of the polypeptide globin subunits are known thus far (An 
updated listing is published at regular intervals by the International 
Haemoglobin Infommtion Centre in Hemoglobin (7)). Many are useful in the 
study of the structure-function relationship in proteins, while most contribute to 
population genetics. A few, such as Hb S, Hb C and Hb E are the cause of 
significant health problems in certain populations. The polymerisation of 
deoxygenated Hb S molecules results in the formation of irreversibly sickled 
cells and the clinical syndrome of sickle cell disease. Although much has been 
learnt about the molecular and cellular pathogenesis of sickle cell disease, 
management remains very unsatisfactory. In the early 1980's, large newborn 
testing programmes :_n New York, Georgia and California in the USA, showed 
that if Hb S homoz:.'gotes could be identified early in life and recruited into 
treatment programmes with pneumococcal vaccination and prophylactic 
penicillin, a significant decrease in infant morbidity and mortality could be 
achieved(8). 
Newborn genetics testing programmes such as these, have become an important 
health tool for the control of genetic disorders. They serve to identify and recruit 
patients into ad hoc clinical care programmes; to identify couples at risk of 
having children with genetic disease and who could benefit from counselling; to 
establish databases for public health planning; and to enhance resources for 
education, training and research. They were initially developed for the care of 
metabolic disease such as Phenylketonuria but they have also contributed 
significantly to improve the care of haemoglobin disorders in certain 
populations. Large programmes also exist for the identification of neonatal 
hypothyroidism. A review of metabolic disease and haemoglobin testing 
programmes serves to ~stablish criteria and protocols for the appropriate design 
of programmes that may be applicable in other areas of medical genetics. 
One of the outcomes of Newborn Haemoglobin Testing Programmes, is the 
ability to collect data on family members, including many heterozygotes and 
identify previously undectected homozygotes. Considerable heterogeneity in the 
phenotypic expression of disease has been uncovered. It is often observed that 
the heterozygous parents of Hb S homozygotes, have quantities of Hb S 
significantly below the expected value of 50%. 
In fact, the proportion of Hb S in a large number of Hb S heterozygotes, falls in 
categories, depending on the number of active a globin genes inherited by the 
carrier. The lower the number of a. globin genes present, the lower the 
proportion of Hb S in cell lysates (Fig. 3). This observation has been explained 
by a lower affinity of the abnormal ~S chains for normal a. chains as compared 
to that of the normal ~A chains. Consequently, whenever a. chains are deficient, 
the post-translational assembly of Hb A is favoured over that of Hb S resulting 
in a lower proportion of Hb S in heterozygotes(9). 
This type of interaction could be representative of a more general type of 
interaction between protein subunits at the level of post-translational assembly. 
Consequently the reh.tive quantities of two heteropolymers which share a 
common subunit and which differ in their rates of assembly can be influenced 
by alteration in the levels of the shared polypeptides. 
Possible examples of this type of interaction could be found in the production of 
the hybrid oncogene products such as jun and fos(lO); or of polymorphic HLA 
heterodimers which may be in linkage with conditions such as Diabetes Mellitus 
Type l(see 11 for review); or among the different collagens present in various 
types of connective tissues and which are assembled from the products of at 
least nine different collagen genes(l2). Many enzymes of metabolism are also 
heteropolymers. Thus this type of interaction between different genes could 
explain heterogeneity in other gene systems in addition to haemoglobin. 
Another outcome of Newborn Haemoglobin Testing is the ability to document 
prospectively the developmental changes in phenotypic features such as the 
. haematological values or other age dependent genetic effects. As many as one 
third of Hb S homozygotes also inherit chromosomes with a globin gene 
deletions - a reminder that even the typical single gene disease can in fact be 
multigenic in origin. 
Up to the age of around 7 years, Hb S homozygotes who differ in their number 
of a globin genes have very similar total haemoglobin values. After this age 
however, those with four a globin genes have worse haemolytic disease and 
lower Hb levels, whereas those with two a globin genes have less severe 
haemolysis, higher Hb levels and higher viscosity with rheologic 
complications(13). Although the age dependent interaction between Hb S 
homozygosity and a-thalassaemia is difficult to explain it could serve as a 
model to account for genetic heterogeneity perhaps for acquired disease with 
strong genetic components. Multiple gene defects could interact at different 
levels during development and aging, though this is somewhat speculative. It 
raises questions that could be profitably pursued in many communities. 
The a globin gene deletions are very common in many ethnic groups. They are 
readily identified with straightforward gene mapping techniques using a gene 
probes (Fig 4). The normal fragment is the 16Kb fragment carrying two a 
globin genes. The 12Kb fragment has only one a globin gene due to a 4Kb 
deletion inclusive of the other a globin gene and is associated with a+ 
thalassaemia. 
Larger deletions are also known to occur among a globin genes. These lead to 
more severe types of a-thalassaemia. In general, the size of the deletions is 
about the same, and their ends map quite closely in DNA. Perhaps, the deletion 
events are associated with a physical looping of the DNA or the ends share 
sequences which predispose this DNA to deletion. 
DNA deletions are a frequent cause of genetic disease. For instance, 
Haemophilia deletions are spread all over the very large Factor VIII gene. In 
haemophilia B it was initially thought that the ocurrence of deletion could 
distinguish between patients with or without immunological inhibitors. In 
Muscular Dystrophy, :he site of deletion in the dystrophin gene most times 
correlates with clinical phenotype although patients with the same deletion and 
different phenotypical picture are also known. The co-inheritance of defects at 
multiple loci, as in the case of Hb S and a. .globin gene deletions should be 
considered in pleiotropic disease. 
On the other hand, deletions are rarely the cause of 13-thalassaemia though they 
have been documented. More often, JHhalassaemia is associat~ with mutations 
in a critical region of th,~ ~-globin gene. These have been difficult and laborious 
to document until recen':ly. 
The approach for the identification of base pair substitutions in thalassaemia and 
other genetic disease has been radically changed by the introduction of the . 
Polymerase Chain Reaction or PCR(14). In this technique, substantial 
quantities of target globin DNA can be reproduced in vitro from exceedingly 
small quantities of starting material. The products can then be sequenced or 
analysed with relatively simple biochemical techniques. A common approach is 
to probe the products with synthetic allele specific oligonucleotides (ASO) 
which detect specific normal or abnormal sequences. We have used this 
approach to identify the molecular types of~ thalassaemia in the Maltese 
population( 15). 
In addition to providing information about gene· control, the documentation. of 
these mutations is clinically useful because it has predictive value on the future 
course of the disease in individual patients. As therapeutic alternatives improve, 
management may be made to fit the needs of the patients. 
Over 110 different mutations accounting for f3-thalassaemia have been identified 
and their distribution in different populations studied (see 6 for current listing). 
Across the Mediterranean there is a gradient of mutations. The prevalance of the 
codon-39 mutation decreases from a maximum of 95% in the Western 
Mediterranean to zero in the Middle East. The opposite is observed for the 
IVSI-110 mutation. In the case of the Maltese population it is remarkable that 
around 60% of the thalassaemiacs thus far identified can be accounted for by 
one mutation i.e. the IVSI nt6 T C. Data have also been obtained that 
objectively quantify the level of expression of the mutant f3+ Thal(IVSI-6 T 
C)(15). 
Similar data have been obtained on another common hereditary disease - cystic 
fibrosis (CF) (see 16 for details). Most commonly CF is due to a three base 
deletion designated DF508. Recent studies in some Mediterranean regions 
showed a lower percentage for this mutation as compared with Northern 
European and American populations. In the case of the Maltese population, out 
of 6 chromosomes thus far studied, 3 have resulted from the 508 deletion. 
Molecular biology has contributed in a remarkable way to our understanding of 
haemoglobin and its abnormalities, whilst biotechnology has equally gained 
from haemoglobin. Our understanding of haemoglobin, provides us with 
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Fig. 1. Isolcct:ric focusing of haemoglobin showing a typical separation of the adult Hb 
A from that of the fo :~tal I-lb F as well as some of the more common abnormal 
haemoglobins such a~.: .Sb S (a2~2 6 Val), common among peoples of African descent 
and Hb F Malta I (or a.2r2 117 Arg), a variant present in about 2% of newborn in Malta. 
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Fig. 2. Developmental c: ianges of the alpha-like and non-::U pha like globins during pre-
natal and postnatal perio '. . 
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Fig.3. The relationship bctw1;:~n a) MCV and b)%HbS and number of a-genes in Hb S 
Hctcrozygotcs. 
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Fig. 4. Diversity ) f normal and abnormal ex and s globin gene specific fragments 
obtained with Xba I and ;m ex globin gene probe. The same fragments hyb1idize with a t; 
globin· gene probe (not shown). The 12 Kb fragment is due to a-thalassaemia-2 (or -al); 
the 16Kb fragmer t is normal (or a.al); the 20Kb fragment is due to a globin gene 
triplication (a.a.al); the 23kb and 27kb arc new fragments which arc considered variants 
of the same or 'rcry similar s globin gene deletions (or -(''aw) occurring on 
chromosomes in tLe absence (X-) or the presence (X+) of the polymorphic Xba I site 5' · 
to the s globin gere. 
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